molsidomine has been researched along with Brain Infarction in 1 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
Brain Infarction: Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, the authors examined the effects of treatment with the NO donor molsidomine with regard to decreasing the incidence of spasm-related delayed brain infarctions and improving clinical outcome in patients with SAH." | 7.83 | Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study. ( Brüning, R; Ehlert, A; Heindel, W; Hesselmann, V; Jacobs, AH; Manthei, G; Pluta, RM; Ringelstein, EB; Schmidt, C; Stummer, W; Wölfer, J, 2016) |
| " In this study, the authors examined the effects of treatment with the NO donor molsidomine with regard to decreasing the incidence of spasm-related delayed brain infarctions and improving clinical outcome in patients with SAH." | 3.83 | Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study. ( Brüning, R; Ehlert, A; Heindel, W; Hesselmann, V; Jacobs, AH; Manthei, G; Pluta, RM; Ringelstein, EB; Schmidt, C; Stummer, W; Wölfer, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ehlert, A | 1 |
| Schmidt, C | 1 |
| Wölfer, J | 1 |
| Manthei, G | 1 |
| Jacobs, AH | 1 |
| Brüning, R | 1 |
| Heindel, W | 1 |
| Ringelstein, EB | 1 |
| Stummer, W | 1 |
| Pluta, RM | 1 |
| Hesselmann, V | 1 |
1 other study available for molsidomine and Brain Infarction
| Article | Year |
|---|---|
Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Infarction; Brain Ischemia; Drug Therapy, Combinat | 2016 |